SNS-062 is primarily investigated for its potential therapeutic applications in treating various forms of cancer. It functions as a kinase inhibitor, specifically targeting Bruton's tyrosine kinase (BTK), which plays a critical role in the survival and proliferation of certain cancer cells, particularly in hematologic malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, SNS-062 disrupts signaling pathways that promote tumor growth and survival, making it a promising candidate for targeted cancer therapy. Additionally, its application is being explored in cases where resistance to other BTK inhibitors has developed, offering a potential treatment option for patients with relapsed or refractory disease. Research is ongoing to evaluate its efficacy, safety, and potential use in combination with other anticancer agents.